Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Muscle-derived autologous stem cell therapy - U.S. Stem Cell

Drug Profile

Muscle-derived autologous stem cell therapy - U.S. Stem Cell

Alternative Names: Implanted autologous skeletal myoblasts - U.S. Stem Cell; Myoblast-derived autologous stem cell therapy - U.S. Stem Cell; MyoCell; MyoCell II; MyoCell SDF-1; Second-generation MyoCell SDF-1 myogenic cell composition - U.S. Stem Cell

Latest Information Update: 27 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioheart
  • Developer AnC Bio; Bioheart; Magnum Cell Therapies; Revita Life Sciences; U.S. Stem Cell
  • Class Cardiovascular therapies; Cell therapies; Heart failure therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Heart failure

Highest Development Phases

  • Marketed Heart failure
  • No development reported Myocardial infarction

Most Recent Events

  • 21 Nov 2017 Muscle-derived autologous stem cell therapy - U.S. Stem Cell is available for licensing as of 21 Nov 2017. http://us-stemcell.com/
  • 21 Nov 2017 U.S. Stem Cell seeks Regenerative Medicine Advance Therapy (RMAT) designation for Heart failure
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Heart-failure in Uganda (Intracardiac)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top